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Introduction {#s1}
============

Osteosarcoma is the most frequent primary bone tumor in children and adults [@pone.0115835-Ritter1]. The metaphyseal regions of long bones, i.e. the regions with high osteoblastic activity, which include the distal femur, proximal tibia and proximal humerus, are the main sites of primary tumor [@pone.0115835-Ottaviani1]. Tumor cells are thought to be of mesenchymal lineage and poorly differentiated, however they still produce osteoid [@pone.0115835-Benayahu1]. With the introduction of chemotherapy the survival rate has risen to 60--75% in the last three decades of the 20^th^ century provided that no metastases are present at the time of diagnosis [@pone.0115835-Bacci1]. Survival rates decrease to less than 30% in metastatic disease [@pone.0115835-Ferguson1], with the lungs as the primary site of metastasis [@pone.0115835-Briccoli1].

Osteosarcomas have a complex karyotype that contain numerous chromosomal aberrations, which consist of gains, amplifications, deletions, translocations and overall aneuploidy [@pone.0115835-Sandberg1]. Frequent copy number gains, suggestive for the presence of oncogenes, have been reported for chromosome regions 1p, 1q, 6p, 8q, and 17p11.2-p12 and copy number losses, suggestive for the presence of tumor suppressor genes, for chromosome regions 3q, 6q, 9, 10, 13, 17p13, and 18q. A number of oncogenes, including *MYC* and *RUNX2*, and tumor suppressor genes, notably *DOCK5*, *CCNE1*, and *LSAMP*, have been shown to be present in the affected regions, but other genes remain to be identified (see recent reviews by Martin *et al*. [@pone.0115835-Martin1] and Kuijjer *et al*. [@pone.0115835-Kuijjer1]).

Each tumor genome harbours a mixture of genetic aberrations affecting genes that are directly responsible for its development (drivers) and random events whereby the affected genes have no biological significance (passengers) [@pone.0115835-Futreal1]. Distinguishing driver from passenger events in the cancer genome is crucial for our understanding of tumor development and will aid to identify novel oncogenes or tumor suppressor genes as potential targets for therapeutical intervention. The identification of driver genes has been a major challenge in earlier copy number studies due to the low resolution and consequently large sizes of the detected aberrations. The increase in resolution of array CGH and SNP platforms in recent years has allowed for the identification of small aberrations that went previously undetected. These sub-microscopic gains and losses, termed focal copy number aberrations (focal CNAs), were reported for different tumor types such as lung, breast, and colon cancer [@pone.0115835-Weir1], [@pone.0115835-Leary1]. Alike large CNAs of somatic origins, they are thought to be the result of a Darwinian-like, yet somatic, evolutionary selection process. Hence, a single gene in a focal CNA would give the tumor a selective growth advantage, which concept is instrumental in the fore laying study. The definition of focal CNAs does not have a biological basis. Based on pragmatic considerations, such as a limited number of genes, size definitions in previous studies and the size of CNVs as defined by Feuk et al [@pone.0115835-Feuk1] led us to select 3 Mb as the upper size limit for a focal CNA [@pone.0115835-Krijgsman1]. To our knowledge, only a few studies in primary human osteosarcoma that use high-resolution arrays have been published. Kuijjer *et al* (2012) [@pone.0115835-Kuijjer2] performed an integrative analysis of copy number and expression profiling in 29 osteosarcoma samples. They identified 31 candidate driver genes, mainly located in regions with recurrent chromosomal losses, of which a substantial number proved to be involved in genomic instability. Previously, we employed a comparable methodology to search for driver genes in chromosome region 17p11.2-p12 in osteosarcoma samples using high-resolution, genome-wide SNP array and expression microarray analyses [@pone.0115835-Both1]. In the present study, we combined both analytical tools to identify novel driver genes in chromosomal regions other than 17p11.2-p12. This was accomplished by identifying the recurrent focal CNAs in the genome of osteosarcomas and by gene expression analysis of the genes they affected.

Materials and Methods {#s2}
=====================

Ethics statement {#s2a}
----------------

Clinical samples were irreversibly anonymised and results of scientific research could not be linked to individual patients. The Committee Medical Ethics of the Academic Medical Center (AMC) specifically waived approval for this study because it falls under paragraph 7∶467 Civil Law Code of The Netherlands.

Patient samples {#s2b}
---------------

A total of 37 osteosarcomas, collected in the AMC, were analyzed in this study. The clinical data of the patients are summarized in [Table 1](#pone-0115835-t001){ref-type="table"}. Sections of the tumors were H&E stained and reviewed by an experienced pathologist (J.Bras) to ensure high tumor cell content (\>90%). Primary human fetal osteoblasts were cultured in osteoblast basal medium with osteoblast growth supplement (Cell Applications, Inc, San Diego, CA USA).

10.1371/journal.pone.0115835.t001

###### Clinicopathological characteristics of patients and tumors.

![](pone.0115835.t001){#pone-0115835-t001-1}

                               PatientCharacteristics   Number of samples (%)
  --------------------------- ------------------------ -----------------------
  Age                                   Mean                    16.8
                                       Median                    16
                                       Range                    6--58
                                                       
  Sex                                   Male                  20 (54.1)
                                       Female                 17 (45.9)
                                                       
  Location of Primary Tumor            Femur                  17 (45.9)
                                    Tibia/Fibula              9 (24.3)
                                      Humerus                 5 (13.5)
                                   Axialskeleton               2 (5.4)
                                       Other                  4 (10.8)
                                                       
  Histological subtype              Osteoblastic              31 (83.8)
                                    Fibroblastic               3 (8.1)
                                   Telangiectatic              2 (5.4)
                                      Unknown                  1 (2.7)
                                                       
  Metastasis at diagnosis                No                   34 (91.9)
                                        Yes                    3 (8.1)

Experimental design {#s2c}
-------------------

DNA and RNA were isolated from alternating sections (10 µm) of fresh frozen tumor samples. A standard proteinase K digestion, followed by a chloroform extraction was used to obtain DNA of high molecular weight. Isolation of RNA was performed using Trizol (Invitrogen, Carlsbad, CA, USA) and a subsequent automated RNeasy protocol (QIAgen, Hilden, Germany). The quality of the RNA was assessed on a BioAnalyzer (Agilent, Santa Clara, CA, USA). Only samples with a RNA Integrity Number (RIN) score higher than 7.5 were included. Human primary fetal osteoblasts were cultured to a confluency of 90% and RNA was isolated to act as a reference in the microarray expression analyses.

Single nucleotide polymorphism (SNP) and expression arrays {#s2d}
----------------------------------------------------------

DNA of 26 osteosarcomas was hybridized for whole-genome copy number variation using Illumina HumanCNV370-Quad BeadChips as previously reported in Both *et al*. (2012) [@pone.0115835-Both1]. The array contained probes for 373,397 SNPs. Processing of DNA samples, hybridization, staining, and scanning of the BeadChips, and primary data extraction were all performed according to the Illumina Infinium II protocol at the array facility of ServiceXS (Leiden, the Netherlands).

Gene expression analysis using Illumina HumanHT-12 v3 Expression Beadchips (Illumina, San Diego USA) was performed on RNA of 31 osteosarcoma samples (of which 20 samples were also analyzed on the SNP array) as previously reported in Both *et al*. (2012) [@pone.0115835-Both1]. Each array contained 48,804 probes, spanning the human transcriptome. Labeling of RNA samples, hybridization, staining, and scanning of the Beadchips, and primary data extraction were all performed according to the Illumina Infinium II protocol, and under ISO 17025 certification, at the array facility of ServiceXS (Leiden, the Netherlands). Expression fold changes of a probe were determined by normalizing the intensity of the average signal in the tumor sample against the average signal in the primary human osteoblasts sample.

The SNP data and expression microarray data have been deposited in NCBI\'s GEO Omnibus and are accessible through GEO Series accession number GSE32964.

SNP and expression array data analysis {#s2e}
--------------------------------------

Median normalized Log2ratios were segmented with Circular Binary Segmentation (CBS) [@pone.0115835-Venkatraman1]. After segmentation samples were mode normalized [@pone.0115835-vandeWiel1]. Chromosomal copy number changes were defined using the RpackageCGHcall [@pone.0115835-vandeWiel1]. Several criteria were applied to distinguish the tumor acquired and thus somatic copy number aberrations (CNAs) from the inherited and thus germline copy number variations, as reviewed by Feuk et al [@pone.0115835-Feuk1]. Germline copy number variants (CNVs) were removed from the dataset in 2 steps: 1) all DNA copy number changes of 3 Mb and smaller were removed if overlapping CNVs regions as archived in the database of genomic variants (DGV), population size and datasets can be found at: <http://dgv.tcag.ca/> [@pone.0115835-Conrad1], 2) all copy number changes of 3 Mb and smaller that showed both recurrent (≥2) gains and losses were marked as CNVs and removed.

For each recurrent focal CNA, the smallest genomic overlap of the focal aberrations and the frequency in the dataset was determined and defined as high frequency region (HFR). Genes were retrieved using biomaRt (R/Bioconductor) and Ensembl (hg18/NCBI 36, ensemble 54).

Expression intensities were transformed to log2ratios with average primary osteoblast intensities as a reference. Array normalization was performed on the log2ratios using LOESS correction on each sample and a quantile normalization to correct for bias between the arrays [@pone.0115835-Smyth1].

For validation purposes the publicly available expression array of 84 osteosarcoma samples and 3 osteoblast samples previously published by Kuijjer et al. (2012) [@pone.0115835-Kuijjer2] was downloaded from NCBI\'s GEO Omnibus database (accession number GSE33383). This was normalized and analyzed using the same tools and settings as for our own dataset. All analyses were performed and plots were made using the statistical programming language R version 2.11.1 and Bioconductor packages (<http://www.r-project.org>).

Selection bias {#s2f}
--------------

The 26 samples used for copy number profiling in this study were previously selected for the presence of an amplification event on chromosome arm 17p [@pone.0115835-Both1]. To determine whether this selection biased the type and frequency CNAs in our sample set, we compared the frequency of aberrations in our sample set with that of an unselected sample set. For the latter, the copy number data (raw log2ratios) of 20 samples, deposited by Kresse et al [@pone.0115835-Kresse1], was downloaded from <http://www.ebi.ac.uk/arrayexpress/>; file E-MEXP-1219 and processed with similar settings as for our samples. Matching of the platforms was performed as described by Van Wieringen *et al*. [@pone.0115835-vanWieringen1] with the "overlapPlus" function. Statistical differences between the matched series were determined using a Wilcoxon test with ties using the R-package CGHtest [@pone.0115835-vandeWiel1]. Apart from the expected higher frequency of 17p gain only one other chromosomal difference, a lower frequency of 7p gain, was observed (FDR q\<0.05). No other significant differences were observed in the frequency of gains and losses between the two sets.

Enrichment analysis {#s2g}
-------------------

To test whether the focal aberrations were enriched for cancer related genes as published in the Cancer Census list (<http://www.sanger.ac.uk/genetics/CGP/Census/>) [@pone.0115835-Futreal2], enrichment analysis was performed as described previously [@pone.0115835-Brosens1].

Results {#s3}
=======

Focal aberrations {#s3a}
-----------------

DNA copy number profiling of 26 osteosarcoma samples showed many regions of frequent gains and losses. As shown in [Fig. 1](#pone-0115835-g001){ref-type="fig"} (top panel), most frequent copy number changes were gains of chromosome arms 1p, 5p, 6p, 8q, 17p, 19 and 21 and losses of chromosome arms 3q, 5q, 6q, 8p, 9p, 10 and 13. Focal copy number changes were found in most samples with a median number of 26 (range: 4--61) for losses and 6 (range: 0--19) for gains per sample. We observed a total of 550 recurrent (n≥2) copy number changes. Representative examples of focal copy number changes are shown in [Fig. 2](#pone-0115835-g002){ref-type="fig"}. Out of the 550 recurrent copy number changes 266 were disregarded since they overlapped with known CNVs. Of the remaining 284 recurrent copy number changes a further 145 regions were disregarded as CNVs since both recurrent (≥2) gains and losses were detected in the dataset at the same location. This leaves a total of 139 unique genomic locations ([Fig. 1](#pone-0115835-g001){ref-type="fig"}, bottom panel) recognized as bonafide focal CNAs. Of these, 72 had at least one gene located within or overlapping the high frequency region (HFR), with a total of 94 genes ([Table 2](#pone-0115835-t002){ref-type="table"}). These focal CNAs were significantly enriched for genes described in the Cancer Gene Census list (p-value  = 0.002, <http://www.sanger.ac.uk/genetics/CGP/>) and include *CBFA2T3*, *EBF1*, *FHIT*, *MYC*, *PTEN* and *RANBP17*. The focal CNAs we identified did not contain known microRNAs.

![Genome-wide frequency plot of all copy number aberrations (top) and of focal copy number aberrations (bottom) in 26 osteosarcoma samples.\
Frequencies of gains (in red) and losses (in blue) are indicated. Vertical bars in B represent detected focal copy number aberrations (\<3 Mb).](pone.0115835.g001){#pone-0115835-g001}

![Representative examples of focal copy number aberrations.\
Log2ratio for each SNP is plotted against its genomic location. Gray lines indicate segment values as derived using circular binary segmentation (CBS). A, Focal deletion encompassing*PAPSS2*, *AFDC1*, and *PTEN* on chromosome 10; B, Focal deletion restricted to *NBEA* on chromosome 13; C, Focal gain including *POU5F1P1*, *MYC*, and *TMEM75* on chromosome 8.](pone.0115835.g002){#pone-0115835-g002}

10.1371/journal.pone.0115835.t002

###### High frequency regions (HFRs) of focal aberrations and gene(s) within or overlapping these HFRs.
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        HFR[1](#nt101){ref-type="table-fn"} Focal abberration   Focal[2](#nt102){ref-type="table-fn"}   Total[3](#nt103){ref-type="table-fn"}                     
  ---- ------------------------------------------------------- --------------------------------------- --------------------------------------- --- ---- ---- ---- ----------------------------------------------------
  1                           68394382                                        68461186                                   67                     2   0    10   0                          GPR177
  1                           166259174                                       166263398                                   4                     2   0    8    0                          IQWD1
  1                           145961855                                       146262362                                  301                    2   1    8    1                     FAM108A2, NBPF11
  2                           51022554                                        51022614                                  0.06                    2   0    3    1                          NRXN1
  2                           153790092                                       154905667                                 1116                    2   0    3    1                      RPRM, GALNT13
  2                           212844992                                       212863839                                  19                     1   3    1    5                          ERBB4
  2                           237017756                                       237067914                                  50                     0   3    1    8                          IQCA1
  3                           38177003                                        38246945                                   70                     1   2    1    6                          OXSR1
  3                           57426028                                        57504090                                   78                     0   2    0    8                         DNAH12L
  3                           59855182                                        59891414                                   36                     0   2    0    9                         **FHIT**
  3                           60208127                                        60420353                                   212                    0   2    0    9                         **FHIT**
  3                           24260772                                        24290280                                   30                     0   3    0    5                           THRB
  3                           32341229                                        32364439                                   23                     0   3    0    6                          CMTM8
  4                           90072621                                        90081252                                    9                     0   2    1    3                         FAM13A1
  4                           183476755                                       184028352                                  552                    0   2    1    7                           ODZ3
  4                           73484965                                        73485361                                  0.396                   0   15   0    17                        ADAMTS3
  5                           170214294                                       170645196                                  431                    1   2    1    5                       **RANBP17**
  5                           55470977                                        55502030                                   31                     0   2    1    10                        ANKRD55
  5                           110611609                                       110683366                                  72                     0   2    0    8                          CAMK4
  5                           135294758                                       135330960                                  36                     0   2    0    8                      FBXL21, LECT2
  5                           158336707                                       158375568                                  39                     0   4    0    7                         **EBF1**
  5                           58765648                                        58766102                                  0.454                   0   5    0    12                         PDE4D
  5                           80023854                                        80024518                                  0.664                   0   11   0    14                          MSH3
  6                           44998738                                        45119343                                   121                    5   0    11   0                          SUPT3H
  6                           13965760                                        14255124                                   289                    2   1    4    1                       CD83, RNF182
  6                           14051934                                        14103151                                   51                     2   1    4    1                          RNF182
  6                           86262042                                        86335470                                   73                     0   3    0    11                      SNX14, NT5E
  6                           110510873                                       110539046                                  28                     0   4    0    12                         WASF1
  7                           57480106                                        57659360                                   179                    2   0    3    1                          ZNF716
  7                           63149422                                        63486197                                   337                    2   0    3    1                      ZNF679, ZNF735
  7                            943615                                          954205                                    11                     1   2    1    3                          ADAP1
  7                           15536047                                        15536441                                  0.394                   0   6    0    7                         TMEM195
  8                           128437695                                       130578879                                 2141                    4   1    14   1                TMEM75, **MYC**, POU5F1P1
  8                           124855221                                       124894704                                  39                     3   0    17   0                         FAM91A1
  8                           132030642                                       132421393                                  391                    2   0    16   0                          ADCY8
  8                           64257961                                        64390486                                   133                    2   1    12   1                          YTHDF3
  8                           145064850                                       145118710                                  54                     2   1    11   1                          PLEC1
  8                           25130171                                        25130291                                  0.12                    1   14   1    15                         DOCK5
  9                            3339487                                         3417226                                   78                     1   2    1    8                           RFX3
  9                           71289871                                        71308842                                   19                     0   2    0    5                          APBA1
  9                           87357661                                        87432833                                   75                     0   3    0    5                         AGTPBP1
  9                           33230225                                        33242111                                   12                     0   8    0    12                         SPINK4
  10                          115580402                                       115675237                                  95                     1   2    1    11                    NHLRC2, DCLRE1A
  10                          25604754                                        25659341                                   55                     1   3    1    15                         GPR158
  10                          15898437                                        15929438                                   31                     0   2    0    16                        C10orf97
  10                          38082301                                        38147982                                   66                     0   2    1    11                         ZNF248
  10                          71648150                                        71656573                                    8                     0   2    0    12                          PPA1
  10                          123566469                                       123752493                                  186                    0   2    1    13                  TACC2, NSMCE4A, ATE1
  10                          89716166                                        89756083                                   40                     0   3    0    14                        **PTEN**
  10                          72166137                                        72172267                                    6                     0   4    0    12                        ADAMTS14
  11                          20922810                                        20971401                                   49                     0   2    0    3                          NELL1
  11                          92517181                                        92571937                                   55                     0   2    0    5                         SLC36A4
  11                          104441220                                       104484303                                  43                     0   2    0    4                          CARD17
  11                          47391562                                        47453463                                   62                     0   3    0    3              CUGBP1, RAPSN, PSMC3, SLC39A13
  11                          102486510                                       102663548                                  177                    0   4    0    5                         DYNC2H1
  12                          51710169                                        51719305                                    9                     0   2    0    5                          EIF4B
  12                          91645948                                        91679726                                   34                     0   2    1    5                         PLEKHG7
  12                          18413696                                        18414167                                  0.471                   0   4    1    7                         PIK3C2G
  13                          92502207                                        93946439                                  1444                    1   2    1    12                       DCT, GPC6
  13                          34399863                                        34517051                                   117                    0   5    0    14                          NBEA
  14                          59138607                                        59161895                                   23                     2   1    5    1                           RTN1
  14                          69961223                                        69998909                                   38                     0   6    0    6                     ADAM21, ADAM21P
  15                          59943982                                        60046989                                   103                    0   2    1    3                          VPS13C
  16                          87557619                                        87557679                                  0.06                    1   2    1    8                       **CBFA2T3**
  16                          87527215                                        87549395                                   22                     1   3    1    9                       **CBFA2T3**
  16                          71734726                                        71798103                                   63                     0   2    0    6                         C16orf47
  16                          45728834                                        45887805                                   159                    0   4    0    6                       ITFG1, NETO2
  17                          37018570                                        37057586                                   39                     0   4    1    7                   KRT42P, KRT17, KRT16
  19                          33996261                                        34984966                                   989                    4   1    12   1    C19orf12, PLEKHF1, POP4, VSTM2B, UQCRFS1, UQCRFSL1
  19                           532070                                          556653                                    25                     0   4    1    4                        HCN2, BSG
  19                          60711906                                        60737394                                   25                     0   4    1    6                           SBK2
  X                           33147645                                        33243866                                   96                     1   6    1    15                          DMD

HFR: common region of focal aberration (gain or loss);

Focal: number of samples with focal aberration;

Total: total number of samples containing the HFR of the focal aberration. Genes in bold have been reported in the Cancer Gene Census list.

Expression of genes in focal CNAs {#s3b}
---------------------------------

Whole genome expression data was available for 31 osteosarcoma samples, including 20 samples from the SNP-array analysis set. These data were used for further analysis of our candidate list of potential driver genes ([Table 2](#pone-0115835-t002){ref-type="table"}). For 85 of the 94 genes at least 1 probe was available on the expression array. Expression fold changes for these genes were calculated by normalizing the intensity of the average signal in the tumor sample against the average signal in the reference osteoblast sample. The genes in the focal copy number losses and in the focal copy number gains were separately assayed for underexpression (expression fold change ≤0.75) and overexpression (expression fold change ≥1.5), respectively. All data are shown in [S1 Table](#pone.0115835.s002){ref-type="supplementary-material"}. From this table a top candidate gene list was extracted with aberrant expression (underexpression in case of focal loss, overexpression in case of focal gain) in ≥35% of the tumors ([Fig. 3](#pone-0115835-g003){ref-type="fig"}). Besides the known tumor suppressor genes *DOCK5* and *PTEN*, genes *OXSR1*, *BSG*, *NT5E*, *PLEKHG7*,*CMTM8*, *NETO2*, *ODZ3*, and *ERBB4* adhered to our criteria and were qualified as novel candidate tumor suppressor genes. Besides the known oncogene *MYC*, genes *CD83*, *RTN1*, *GRP177*, and *POP4* adhered to our criteria and were qualified as novel candidate oncogenes.

![Genes in focal losses with underexpression (FC\<0.75, A) and in focal gains with overexpression (FC\>1.5, B) in more than 35% of osteosarcomas.\
Green: expression fold change (FC) \<0.75 of the gene in the tumor relative to osteoblasts (underexpression). Red: expression fold change (FC) \>1.50 of the gene in the tumor relative to osteoblasts (overexpression). For each gene, the number (n) and fraction (%) of osteosarcomas with the indicated fold change (FC) are given.](pone.0115835.g003){#pone-0115835-g003}

Validation analysis {#s3c}
-------------------

To confirm our findings of the proposed candidate genes in an independent dataset we used expression data for 84 osteosarcoma samples and 3 osteoblast samples, which were generated by Kuijjer et al [@pone.0115835-Kuijjer2]. Expression fold changes for our candidate genes were calculated by normalizing their expression level in the osteosarcoma samples against the mean expression level in the osteoblast reference samples. Next, they were assayed for their frequency of underexpression (expression fold change ≤0.75, in case of a candidate tumor suppressor gene) or overexpression (expression fold change ≥1.5, in case of a candidate oncogene) in the osteosarcoma samples (see [S1 Fig](#pone.0115835.s001){ref-type="supplementary-material"}.). In [Table 3](#pone-0115835-t003){ref-type="table"}, the frequencies of involvement of our candidate driver genes in this validation set are summarized and compared with those in our own osteosarcoma set. Considering a frequency of involvement for a driver gene of at least 35% as a convincing event, we conclude that the validation set confirms our identification of *OXSR1, BSG, NT5E, CMTM8*, and *NETO2* as novel candidate tumor suppressor genes and of *CD83, RTN1*, and *GPR177* as novel oncogenes.

10.1371/journal.pone.0115835.t003

###### Validation of identified candidate tumor suppressor genes and oncogenes in an independent dataset.
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  Gene                               Our set             Validation set
  --------------------------------- --------- -------------------------------------
  Candidate tumor suppressor gene             
  OXSR1                                97                      89
  BSG                                  94                      70
  NT5E                                 84                      93
  (DOCK5                               81                     90\)
  PLEKHG7                              77                       0
  CMTM8                                68                      65
  NETO2                                61                      60
  ODZ3                                 61      NI[1](#nt106){ref-type="table-fn"}
  (PTEN                                45      NI[2](#nt107){ref-type="table-fn"})
  ERBB4                                35                       0
  Candidate oncogene                          
  CD83                                 74                      51
  RTN1                                 58                      74
  GPR177                               48                      43
  (MYC                                 45                      4\)
  POP4                                 35                      18

Frequency of involvement (percentage underexpression of a candidate tumorsuppressor gene and percentage overexpression of a candidate oncogene) in the original and validation set

Known tumor suppressor genes (*DOCK5*, *PTEN*) and oncogene (*MYC*) between brackets

No information. Applied probe does not recognize *ODZ3* in 4q35.1

No information. Applied probe recognizes not only *PTEN* on 10q23.31, but also the expressed pseudogene (*PTENP1*) in 9p13.3.

Discussion {#s4}
==========

Due to the complex landscape of genomic rearrangements in osteosarcomas the identification of driver genes remains a challenging task. Nonetheless, by analysis of focal aberrations, we identified potential new and known genes driving osteosarcoma tumorigenesis. In our set of 26 osteosarcoma samples, 94 genes were identified within recurrent focal aberrations. Some were found in 2 samples only, others in a large portion of the samples, such as *DOCK5* (14/26) and *ADAMTS3* (15/26) ([Table 2](#pone-0115835-t002){ref-type="table"}). It should be noted that the previously published amplifications in the 17p11.2-p12 region and the potential oncogenes therein [@pone.0115835-Both1] were not identified in this study since these amplifications were generally large (\>3 Mb), and hence not recognized as focal CNAs in this study.

For most of the genes in the focal aberrations (85 of 94) expression data in a set of 31 osteosarcoma samples were available. This allowed us to identify the genes of which the expression status (over- or underexpression) in these tumors was frequently (\>35%) in accordance to their copy number status (gain or loss), as deduced from the focal aberration analyses. These were, in addition to the known tumor suppressor genes *PTEN* and *DOCK5* and the known oncogene *MYC*, in total 8 candidate tumor suppressor genes and 4 candidate oncogenes as potential new driver genes in osteosarcoma tumorigenesis ([Table 3](#pone-0115835-t003){ref-type="table"}). As discussed below for the individual genes, validation using an independent dataset, confirmed the candidacy of most of the driver genes that we identified.

Known tumor suppressor genes and oncogenes found in our analysis {#s4a}
----------------------------------------------------------------

The strength of the applied approach of focal aberration analysis might be concluded from the enrichment of the focal CNAs we identified in our osteosarcoma dataset with driver genes from the Cancer Census list [@pone.0115835-Futreal2] and in particular the identification of *PTEN*, *DOCK5*, and *MYC* as known driver genes in osteosarcoma. For instance, *PTEN* has been implicated in osteosarcoma tumorigenesis in a multitude of studies. Loss of the *PTEN* gene has been reported in patient samples [@pone.0115835-Freeman1] and lower *PTEN* expression levels in cell lines [@pone.0115835-Lee1]. However, because the available probe in the validation set proved to be not specific to *PTEN*, we could not confirm its frequent involvement as a tumor suppressor gene in this set. We found frequent underexpression of *DOCK5* in our set as well as in the validation set. Expression of *DOCK5* is essential for bone differentiation in osteoclasts [@pone.0115835-Brazier1]. Recently, *DOCK5* expression was shown to be down-regulated in osteosarcoma [@pone.0115835-Sadikovic1]. The *MYC* oncogene is involved in many tumor types, including carcinomas of cervix, lung, breast, colon, and stomach, and also in osteosarcoma [@pone.0115835-Radig1]. MYC acts as a cell proliferation controller and overexpression, as found in a multitude of tumors as well as in our dataset, drives higher proliferation and blocks cell differentiation. Furthermore, a secondary effect of MYC overexpression is the induction of chromosomal instability by faulty control of the G1-S checkpoint [@pone.0115835-Li1]. For unknown reasons, we could not confirm the frequent overexpression of *MYC*, as noted in our osteosarcoma set, in the validation set. Unfortunately, no expression data for another *MYC* probe in the latter set was available to substantiate this unexpected result.

Newly identified candidate tumor suppressor genes {#s4b}
-------------------------------------------------

In our analysis eight new candidate tumor suppressor genes were identified, *OXSR1* (3p22.2), *BSG*(19p13.3), *NT5E*(6q14.3), *PLEKHG7*(12q22), *CMTM8*(3p22.3), *NETO2*(16q12.1), *ODZ3*(4q35.1) and *ERBB4*(2q34). However, since the involvement of *PLEKHG7* and *ERBB4* could not be confirmed in the validation set and conflicting data have been reported for *OXSR1*, *BSG*, *NT5E*, and *NETO2* in other tumor types (summarized in [Table 4](#pone-0115835-t004){ref-type="table"}), we consider these as less probable candidate tumor suppressor genes in osteosarcoma tumorigenesis.

10.1371/journal.pone.0115835.t004

###### Excluded newly identified driver genes.

![](pone.0115835.t004){#pone-0115835-t004-4}

  Gene                                                                                                                   Reason for exclusion
  ------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Candidate tumor suppressor gene(s)   
  *PLEKHG7, ERBB4*                                                                                Underexpression in our set, but no confirmation in validation set
  *OXSR1, NT5E, NETO2*                                  Underexpression in our set and validation set, but conflicting expression data in other tumor types [@pone.0115835-Calicchio1]--[@pone.0115835-Wang1]
  *BSG*                                                 Underexpression in our set and validation set, conflicting with oncogenic role in other tumor types [@pone.0115835-Nakamura1]--[@pone.0115835-Sweeny1]
  Candidate oncogene                   
  *CD83*                                Overexpression in our set and validation set of this cell surface marker most probably related to altered tumor microenvironment, but not to tumor formation [@pone.0115835-Fujimoto1]
  *RTN1*                                                Overexpression in our set and validation set conflicts with tumor suppressor role in other tumor types [@pone.0115835-Astolfi1]--[@pone.0115835-Fazi1]

In several tumor types, indications have been found for a tumor suppressor function of the *CMTM8* gene product. In osteosarcoma, it was demonstrated that CMTM8, also known as CKLFSF8, suppresses the EGFR signaling pathway [@pone.0115835-Jin1]. *CMTM8* underexpression may therefore result in upregulation of EGFR signaling. The latter was recently shown to suppress osteoblast differentiation and to inhibit expression of the osteoblastic transcription factors Runx2 and Osterix, which may lead to the development of immature osteoblastic-like cells characteristic of osteosarcoma [@pone.0115835-Zhu1]. In other tumor types, overexpression of *CMTM8* has been shown to result in tumor cell apoptosis [@pone.0115835-Jin2], [@pone.0115835-Li2]. In addition, in hepatocellular carcinoma cells and immortalized breast epithelial cells (MCF-10A), downregulation of *CMTM8* was found to result in a transition from an epithelial to a mesenchymal phenotype. This transition results from the loss of c-Met inhibition by CMTM8, which in turn activates migration, invasive growth and cancer malignancy [@pone.0115835-Salvi1], [@pone.0115835-Zhang1]. Interestingly, c-Met is known to be upregulated in human sarcomas [@pone.0115835-Teicher1].We found *CMTM8* underexpression in a considerable number of cases in our original set and in the validation set. This gene may therefore have a tumor suppressor gene function in osteosarcoma tumorigenesis.

We found *ODZ3* to be underexpressed in a considerable fraction of the investigated osteosarcomas but, because of lack of a specific probe, were unable to validate the expression data for this gene in the independent set. Deletion of *ODZ3* and low mRNA expression has been noted to occur in neuroblastoma [@pone.0115835-Molenaar1]. In addition, in the latter study the low expression level of this gene proved to be associated with a poor prognosis. Whether *ODZ3* has a similar tumor suppressor gene function in osteosarcoma remains to be established.

Newly identified candidate oncogenes {#s4c}
------------------------------------

We identified three genes located in focal gains and overexpressed in a significant fraction of both osteosarcoma sets: *CD83* (6p23), *RTN1* (14q23.1), and *GPR177* (*WLS*/*EVI*) (1p31.3). However, as briefly explained in [Table 4](#pone-0115835-t004){ref-type="table"}, we consider *CD83* and *RTN1* as less probable candidate oncogenes in osteosarcoma tumorigenesis.

No information is available about the expression of *GPr177(WLS/EVI)* in osteosarcomas. It is known that physiologically normal GPR177 protein levels are essential for proper osteoblast differentiation and mineralization [@pone.0115835-Zhong1]. The *GPR177* gene encodes an upstream regulator of the Wnt signaling pathway. However, the status of this pathway in osteosarcoma is unclear. Some papers report active Wnt signaling [@pone.0115835-Iwaya1], [@pone.0115835-Kansara1], while others find that the Wnt signaling pathway is inactivated in this tumor [@pone.0115835-Cai1], [@pone.0115835-Du1]. GPR177 has been found to be overexpressed in glioma [@pone.0115835-Augustin1]. Moreover, GPR177 proved to be indispensable for Wnt-induced breast tumor formation [@pone.0115835-Maruyama1]. In accordance with the latter observations, we found frequent overexpression of *GPR177* in both osteosarcoma sets. Taken together, these data suggest a potential oncogenic role for *GPR177* in osteosarcoma tumorigenesis.

Conclusions {#s5}
===========

Based on their frequent aberrant copy number in our osteosarcoma set, the frequent under-, respectively, overexpression in our osteosarcoma set as well as in a validation set, and their documented involvement in other tumor types, we identified *CMTM8*, and possibly also *ODZ3*, as a new candidate tumor suppressor gene, and *GPR177* as a new candidate oncogene involved in osteosarcoma tumorigenesis.

Supporting Information {#s6}
======================

###### 

Genes in focal losses with underexpression (FC\<0.75, A) and in focal gains with overexpression (FC\>1.5, B) in more than 35% of osteosarcomas in the validation dataset. Green: expression fold change (FC) \<0.75 of the gene in the tumor relative to osteoblasts (underexpression). Red: expression fold change (FC) \>1.50 of the gene in the tumor relative to osteoblasts (overexpression). For each gene, the number (n) and fraction (%) of osteosarcomas with the indicated fold change (FC) are given.

(XLSX)
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Click here for additional data file.

###### 

Expression fold change for all genes in focal losses (upper panel) or focal gains (lower panel) in 31 osteosarcoma samples. Green: expression fold change (FC) \<0.75 of the gene in the tumor relative to osteoblasts (underexpression). Red: expression fold change (FC) \>1.50 of the gene in the tumor relative to osteoblasts (overexpression). For each gene, the number (n) and fraction (%) of osteosarcomas with the indicated fold change (FC) are given.

(XLSX)

###### 

Click here for additional data file.
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